CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 59 enrolled
Drug / intervention
Metformin Hydrochloride Extended Release 750mgdrug
Likely dose
Metformin Hydrochloride Extended Release 750mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02176161
NCT02176161Phase 2Completed
CompareCT.gov

Phase II Clinical Study of Effect of Metformin on Prostate Specific Antigen Doubling Time

NYU Langone Health·interventional·Posted Jun 26, 2014·Updated Oct 18, 2022

In Brief

A Phase 2 clinical trial evaluating Metformin Hydrochloride Extended Release 750mg for Prostate Cancer and Prostate Cancer Recurrent. Completed, enrolled 59 participants across 1 site.

Detailed Summary

This is a Phase II clinical study to determine if Metformin can increase Prostate Specific Antigen (PSA) doubling time for patients with Prostate Cancer who have failed primary treatment with radiation, or surgical patients that are at high risk for recurrence based on surgical pathology. Men with confirmed prostate cancer and rising serum PSA levels will receive Metformin and will be monitored for PSA response and disease progression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Prostate Cancer Recurrent
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 26, 2014
Enrollment StartJun 1, 2014
Primary CompletionJul 21, 2021
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 12.0 years ago

Interventions

Metformin Hydrochloride Extended Release 750mgdrug

Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.